Slideshow
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
This slideshow reviews pembrolizumab (Keytruda), indicated for the treatment of unresectable or metastatic melanoma, metastatic non-small cell lung cancer (NSCLC), and recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).
Table of Contents
Slide 4: Dosage and Administration
Slide 12: Cautions, Effects, and Interactions
Slide 19: What to Tell Your Patient
Slide 27: Reference